436 related articles for article (PubMed ID: 19338578)
1. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
2. A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription.
Krätzner R; Fröhlich F; Lepler K; Schröder M; Röher K; Dickel C; Tzvetkov MV; Quentin T; Oetjen E; Knepel W
Mol Pharmacol; 2008 Feb; 73(2):509-17. PubMed ID: 17962386
[TBL] [Abstract][Full Text] [Related]
3. Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity.
Schinner S; Dellas C; Schroder M; Heinlein CA; Chang C; Fischer J; Knepel W
J Biol Chem; 2002 Jan; 277(3):1941-8. PubMed ID: 11707457
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
Kast-Woelbern HR; Dana SL; Cesario RM; Sun L; de Grandpre LY; Brooks ME; Osburn DL; Reifel-Miller A; Klausing K; Leibowitz MD
J Biol Chem; 2004 Jun; 279(23):23908-15. PubMed ID: 15073165
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1.
Ungaro P; Mirra P; Oriente F; Nigro C; Ciccarelli M; Vastolo V; Longo M; Perruolo G; Spinelli R; Formisano P; Miele C; Beguinot F
J Biol Chem; 2012 Dec; 287(51):42951-61. PubMed ID: 23105093
[TBL] [Abstract][Full Text] [Related]
6. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.
Deng T; Shan S; Li PP; Shen ZF; Lu XP; Cheng J; Ning ZQ
Endocrinology; 2006 Feb; 147(2):875-84. PubMed ID: 16269451
[TBL] [Abstract][Full Text] [Related]
8. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
Armoni M; Kritz N; Harel C; Bar-Yoseph F; Chen H; Quon MJ; Karnieli E
J Biol Chem; 2003 Aug; 278(33):30614-23. PubMed ID: 12777391
[TBL] [Abstract][Full Text] [Related]
10. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells.
Kim HS; Hwang YC; Koo SH; Park KS; Lee MS; Kim KW; Lee MK
PLoS One; 2013; 8(1):e50128. PubMed ID: 23372643
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
12. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
13. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
14. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
15. The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-gamma.
Todorov VT; Desch M; Schubert T; Kurtz A
Endocrinology; 2008 Sep; 149(9):4647-57. PubMed ID: 18483152
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone promotes PPARγ-dependent and -independent alterations in gene expression in mouse islets.
Welters HJ; El Ouaamari A; Kawamori D; Meyer J; Hu J; Smith DM; Kulkarni RN
Endocrinology; 2012 Oct; 153(10):4593-9. PubMed ID: 22807489
[TBL] [Abstract][Full Text] [Related]
17. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
[TBL] [Abstract][Full Text] [Related]
18. Expression and functional activity of PPARgamma in pancreatic beta cells.
Welters HJ; McBain SC; Tadayyon M; Scarpello JH; Smith SA; Morgan NG
Br J Pharmacol; 2004 Aug; 142(7):1162-70. PubMed ID: 15237101
[TBL] [Abstract][Full Text] [Related]
19. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosiglitazone and metformin on pancreatic beta cell gene expression.
Richardson H; Campbell SC; Smith SA; Macfarlane WM
Diabetologia; 2006 Apr; 49(4):685-96. PubMed ID: 16489446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
